Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
checkpoint inhibitors
Biotech
Crescent inks GlycoMimetics merger, securing listing and $200M
Crescent is part of the pack of drug developers targeting the PD-1xVEGF bispecific opportunity.
Nick Paul Taylor
Oct 29, 2024 10:20am
Merck's LAG-3 combo fails colorectal cancer phase 3 study
Sep 25, 2024 8:35am
ESMO: Innovent links cytokine to colorectal cancer responses
Sep 18, 2024 9:53am
Incyte drops two PD-L1 drugs as part of 2nd pipeline clear-out
Jul 30, 2024 8:14am
Boehringer offers up to $1.3B for checkpoint inhibitor biotech
Jul 29, 2024 10:31am
AI model from NIH, MSKCC predicts immunotherapy responses: study
Jun 4, 2024 12:42pm
